Gomes Anna, Jainandunsing Jayant S, van Assen Sander, van Geel Peter Paul, Sinha Bhanu, Gelsomino Sandro, Johnson Daniel M, Natour Ehsan
Department of Medical Microbiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
Department of Anesthesiology, University of Groningen, University Medical Center Groningen, Groningen, Netherlands.
J Cardiothorac Surg. 2018 Apr 19;13(1):32. doi: 10.1186/s13019-018-0715-8.
Surgical treatment of complicated aortic valve endocarditis often is challenging, even for experienced surgeons. We aim at demonstrating a standardized surgical approach by stentless bioprostheses for the treatment of aortic valve endocarditis complicated by paravalvular abscess formation.
Sixteen patients presenting with aortic valve endocarditis (4 native and 12 prosthetic valves) and paravalvular abscess formation at various localizations and to different extents were treated by a standardized approach using stentless bioprostheses. The procedure consisted of thorough debridement, root replacement with reimplantation of the coronary arteries and correction of accompanying pathologies (aortoventricular and aortomitral dehiscence, septum derangements, Gerbode defect, total atrioventricular conduction block, mitral and tricuspid valve involvement).
All highly complex patients included (14 males and 2 females; median age 63 years [range 31-77]) could be successfully treated with stentless bioprostheses as aortic root replacement. Radical surgical debridement of infected tissue with anatomical recontruction was feasible. Although predicted operative mortality was high (median logarithmic EuroSCORE I of 40.7 [range 12.8-68.3]), in-hospital and 30-day mortality rates were favorable (18.8 and 12.5% respectively).
Repair of active aortic valve endocarditis complicated by paravalvular abscess formation and destruction of the left ventricular outflow tract with stentless bioprosthesis is a valuable option for both native and prosthetic valves. It presents a standardized approach with a high success rate for complete debridement, is readily available, and yields comparable clinical outcomes to the historical gold standard, repair by homografts. Additionally, use of one type of prosthesis reduces logistical issues and purchasing costs.
即使对于经验丰富的外科医生而言,复杂主动脉瓣心内膜炎的外科治疗通常也具有挑战性。我们旨在展示一种使用无支架生物瓣膜治疗并发瓣周脓肿形成的主动脉瓣心内膜炎的标准化手术方法。
16例患有主动脉瓣心内膜炎(4例为原生瓣膜,12例为人工瓣膜)且瓣周脓肿形成部位和程度各异的患者,采用使用无支架生物瓣膜的标准化方法进行治疗。该手术包括彻底清创、冠状动脉再植入的根部置换以及对伴随病变(主动脉心室和主动脉二尖瓣裂开、间隔紊乱、Gerbode缺损、完全性房室传导阻滞、二尖瓣和三尖瓣受累)的矫正。
所有纳入的高复杂性患者(14例男性和2例女性;中位年龄63岁[范围31 - 77岁])均能够成功使用无支架生物瓣膜进行主动脉根部置换治疗。对感染组织进行根治性手术清创并进行解剖重建是可行的。尽管预计手术死亡率较高(中位对数欧洲心脏手术风险评估系统I为40.7[范围12.8 - 68.3]),但住院死亡率和30天死亡率均较为理想(分别为18.8%和12.5%)。
对于原生瓣膜和人工瓣膜,使用无支架生物瓣膜修复并发瓣周脓肿形成及左心室流出道破坏的活动性主动脉瓣心内膜炎都是一种有价值的选择。它提供了一种标准化方法,清创成功率高,易于获得,并且临床结果与历史金标准同种异体移植物修复相当。此外,使用单一类型的瓣膜可减少后勤问题和采购成本。